Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

BMC Cancer

Research

Emmanuel Desandes¹  Loïc Chaigneau²  Jean-Christophe Ruzic³  Valérie Lebrun-Ly⁴  Juliane Berchoud⁵  Mickaël Ropars⁶  Jean-Claude Gentet⁷  Florence Duffaud⁷  Marie-Pierre Castex⁸  Pascale Blouin⁹  Louis-Romée Le Nail⁹  Grégory Cherrier⁹  Esma Saada^1,10  Christophe Perrin^1,11  Sharmini Varatharajah^1,12  Sylvain Causeret^1,13  Cécile Guillemet^1,14  Pascale Dubray-Longeras^1,15  Jean-Yves Blay^1,16  Françoise Ducimetière^1,16  Magali Morelle^1,16  Claire Chemin^1,16  François Gouin^1,17  Perrine Marec-Bérard^1,18  Cyril Lervat^1,19  Nicolas Penel^1,19  Sébastien Carrère^2,20  Pierre Kubicek^2,21  Nathalie Gaspar^2,22  Axel Le Cesne^2,22  Charles Honoré^2,22  Antoine Italiano^2,23  Pascaline Boudou-Rouquette^2,24  Philippe Anract^2,24  Éric Mascard^2,25  Stéphanie Pannier^2,25  Céleste Lebbe^2,26  Jean-Pierre Lotz^2,27  Maud Toulmonde^2,28  Cécile Vérité^2,28  Christine Chevreau^2,29  Pauline Soibinet-Oudot^3,30  François Bertucci^3,31  Jean-Emmanuel Kurtz^3,32  Maria Rios^3,33  Emmanuelle Bompas^3,34  Nadège Corradini^3,35  Daniel Orbach^3,36  Sophie Piperno-Neumann^3,36  Valérie Laurence^3,36 

[1] CHRU Nancy, Centre de Recherche en Epidémiologie et en Statistique Sorbonne-Paris Cité (CRESS), UMR 1153, INSERM, Université de Paris-Descartes, Paris, France;CHU Besançon, Besançon, France;CHU La Réunion Mayotte, Saint-Pierre, France;CHU Limoges, Limoges, France;CHU Nantes, Nantes, France;CHU Rennes, Rennes, France;CHU Timone, Marseille, France;CHU Toulouse, Toulouse, France;CHU Tours, Tours, France;Centre Antoine Lacassagne, Nice, France;Centre Eugène Marquis, Rennes, France;Centre François Baclesse, Caen, France;Centre Georges François Leclerc, Dijon, France;Centre Henri Becquerel, Rouen, France;Centre Jean Perrin, Clermont-Ferrand, France;Centre Léon Bérard, Lyon, France;Centre Léon Bérard, Lyon, France;CHU Nantes, Nantes, France;Centre Léon Bérard, Lyon, France;Institute of Pediatric Hematology and Oncology, Lyon, France;Centre Oscar Lambret, Lille, France;Centre Val d’Aurelle ICM, Montpellier, France;Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Angers, France;Centre Léon Bérard, Lyon, France;Gustave Roussy, Villejuif, France;Gustave Roussy, Villejuif, France;Institut Bergonié, Bordeaux, France;Hôpital Cochin, Paris, France;Hôpital Necker, Paris, France;Hôpital Saint-Louis, Paris, France;Hôpital Tenon, Paris, France;Institut Bergonié, Bordeaux, France;Institut Claudius Régaud IUCT Toulouse, Toulouse, France;Institut Jean Godinot, Reims, France;Institut Paoli-Calmettes, Marseille, France;Institut de Cancérologie Strasbourg-Europe ICANS, Strasbourg, France;Institut de Cancérologie de Lorraine, Nancy, France;Institut de Cancérologie de l’Ouest, Nantes, France;Institute of Pediatric Hematology and Oncology, Lyon, France;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France;

关键词: Adolescents and young adults;    AYAs;    Sarcoma;    Management;    Multidisciplinary tumor board;    Reference centers;    Survival;    NETSARC;   

DOI  :  10.1186/s12885-023-10556-4

 received in 2022-05-21, accepted in 2023-01-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level.Patients and methodsNETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15–30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors.ResultsAmong 3,227 patients aged 15–30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3–83.6) in AYA in RSC and 82.7% (95%CI 79.4–85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively).ConclusionsThis study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq379.gif

41116_2022_35_Article_IEq372.gif